Abilify MyCite, the first digital pill. Where does all that silicone go?

Last Updated on

November 16, 2017 – The American Food & Drug Administration (FDA) just approved Ability MyCite,  a pill with a sensor that digitally tracks if patients have ingested their medication. This is a very first in its class at the new age of digital health.

Digital health. Th pill with the chip.

Originally  Aripiprazole (Abilify)  was approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. The all new Aripiprazole (Abilify MyCite) (i.e., aripiprazole tablets with an sensor) is approved for the same indictions. It comes, however, with an ingestible sensor embedded in the pill that records that the medication was taken. Thus, the Abilify MyCite features a sensor the size of a grain of sand made of silicone, copper, and magnesium. An electrical signal is activated when the sensor comes into contact with stomach acid. A patch the patient wears on their left rib cage receives the signal several minutes after the pill is ingested. The patch then sends data like the time the pill was taken and the dosage to a smartphone app over Bluetooth. The patch also records activity levels, sleeping patterns, steps taken, activity, and heart rate, and must be replaced every seven days. The patient’s doctor and up to four other people chosen by the patient, including family members, can access the information. The patient can revoke access at any time. It is assumed that the sensor as such  passes through the body naturally.

Schizophrenia is a chronic, severe and disabling brain disorder. About 1 percent of Americans have this illness. Typically, symptoms are first seen in adults younger than 30 years of age. Symptoms of those with schizophrenia include hearing voices, believing other people are reading their minds or controlling their

Self portrait of a patient with Schizophrenia in the digital age.

thoughts, and being suspicious or withdrawn. Bipolar disorder, also known as manic-depressive illness, is another brain disorder that causes unusual shifts in mood, energy, activity levels and the ability to carry out day-to-day tasks. The symptoms of bipolar disorder include alternating periods of depression and high or irritable mood, increased activity and restlessness, racing thoughts, talking fast, impulsive behavior and a decreased need for sleep.

The drug label of Aripiprazole (Abilify MyCite), as does the drug label of the regular Aripiprazole (Abilify) which is approved since 2002, contains a Boxed Warning alerting health care professionals that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole (Abilify MyCite) is not approved to treat patients with dementia-related psychosis. The Boxed Warning also warns about an increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants. The safety and effectiveness of Aripiprazole (Abilify MyCite) have not been established in pediatric patients. Patients should be monitored for worsening and emergence of suicidal thoughts and behaviors. Aripiprazole (Abilify MyCite) must be dispensed with a Patient Medication Guide that describes important information about the drug’s uses and risks. Other common adverse drug effects reported by patients taking Aripiprazole (Abilify) were nausea, vomiting, constipation, headache, dizziness, uncontrollable limb and body movements (akathisia), anxiety, insomnia, and restlessness. With Aripiprazole (Abilify MyCite, skin irritation at the site of the MyCite patch placement may occur in some patients.

Patients should be well aware of the fact that new technology per se does not alleviate the serious health problems that come along for some patients who take Aripiprazole (Abilify) or antidepressant drugs in general, or their compliance with treatment. However, according to FDA, being able to track ingestion of medications prescribed for mental illness may be useful for some patients, and FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers. Thus, Aripiprazole (Abilify MyCite) comes after years of venture research between Japanese pharmaceutical company Otsuka and digital medicine service Proteus Digital Health, which makes the sensor. Aripiprazole (Abilify MyCite) is one way to address the prevalent problem of patients not taking their medication correctly, with the IMS Institute estimating that the improper and unnecessary use of medicine cost the US healthcare sector over $200 billion in 2012.

Some serious questions might arise around digital pills, however. One question would be on what a digital pill might mean for patient privacy. Some are worried that tracking such pills will be a step towards punishing patients who don’t comply for whatever reason with treatment. This could mean that digital pills have the potential to improve public health but also to foster more mistrust instead of trust between caregivers and patients. Not to forget the role of insurers who potentially will have access to all these patient data as well. A second question could be as to the health effects on patients who are continouly exposed to silicon and all the other materials who make up the sensor. Where does all that silicone go? And last but not least, how to prevent patients from simply deceiving the system by exposing the sensor to 1 N HCl outside of the body in order to trigger the communication?

_______________________

Tags: , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • MicroRNA exhibit unexpected function in driving cancer February 20, 2020
    Researchers long thought that only one strand of a double-stranded microRNA can silence genes. Though recent evidence has challenged that dogma, it's unclear what the other strand does, and how the two may be involved in cancer. New research from Thomas Jefferson University has revealed that both strands of some microRNA coordinate to act on […]
  • New therapy stops seizures in mouse model of rare childhood epilepsy February 20, 2020
    Seizure disorders in babies are frightening and heartbreaking. A new basic science breakthrough offers hope for a potential treatment for rare developmental and epileptic encephalopathies resulting from a single genetic mutation. The gene in question, called SCN8A, controls a sodium channel that allows neurons to transmit an electric signal. When this gene is mutated, these […]
  • Scientists find many gene 'drivers' of cancer, but warn: Don't ignore 'passengers' February 20, 2020
    A massive analysis of the entire genomes of 2,658 people with 38 different types of cancer has identified mutations in 179 genes and gene regulators as "drivers"—variations in DNA sequences that lead to the development of cancer.
  • A deep dive into cellular aging February 20, 2020
    Scientists at Sanford Burnham Prebys Medical Discovery Institute and Harvard University have discovered that mitochondria trigger senescence, the sleep-like state of aged cells, through communication with the cell's nucleus—and identified an FDA-approved drug that helped suppress the damaging effects of the condition in cells and mice. The discovery, published in Genes & Development, could lead […]
  • New model of C. elegans helps progress study of rare genetic disease February 20, 2020
    The IDIBELL Neurometabolic Diseases group, with international collaboration, has identified a model of chromosome X-linked adrenoleukodystrophy (X-ALD) in C. elegans. X-ALD is a rare disorder of the nervous system with no available treatment.
  • Half of transgender youth avoid disclosing gender identity to a health care provider February 20, 2020
    Researchers surveyed 153 transgender youths receiving gender-affirming care at a specialty clinic, and even in this relatively 'out' population, nearly half reported intentionally hiding their gender identity from a health care provider outside the clinic.
  • Fifty years of data show new changes in bird migration February 20, 2020
    A growing body of research shows that birds' spring migration has been getting earlier and earlier in recent decades. New research from The Auk: Ornithological Advances on Black-throated Blue Warblers, a common songbird that migrates from Canada and the eastern US to Central America and back every year, uses fifty years of bird-banding data to […]
  • New study supports the safety of varenicline February 20, 2020
    A real-world study of over 600,000 adult participants without a history of depression has found that the stop-smoking medication varenicline (marketed as Chantix and Champix) does not appear to be associated with an increased risk of cardiovascular or neuropsychiatric hospitalization compared with nicotine replacement therapy (NRT). These findings confirm those of earlier clinical trials, providing […]
  • New study indicates amino acid may be useful in treating ALS February 20, 2020
    A naturally occurring amino acid is gaining attention as a possible treatment for ALS following a new study published in the Journal of Neuropathology & Experimental Neurology. It showed the amino acid, L-serine, successfully reduced ALS-like changes in an animal model of ALS. After exposure to the cyanobacterial neurotoxin, BMAA, vervets developed pathology similar to […]
  • Patients frequently refuse insulin therapy, delaying blood sugar control February 20, 2020
    Investigators from Brigham and Women's Hospital find that more than 40% of patients refuse a physician's recommendation of insulin therapy. The study also finds that patients who decline insulin therapy had worse blood sugar control and it took them significantly longer to lower their blood sugar levels than patients who began insulin therapy.
Top